Second affiliated Hospital of Jilin University, Changchun, China.
BMC Ophthalmol. 2021 May 7;21(1):201. doi: 10.1186/s12886-021-01953-z.
Numerous cases with ocular toxicity secondary to tamoxifen have been reported, and became more apparent with keratopathy, cataract, optic neuritis, macular holes, crystalline retinopathy with or without cystoid macular edema (CME). Withdrawing tamoxifen with the approval of the oncologist is the major treatment for cases with tamoxifen-induced retinopathy.
We herein reported a patient with a two-year history of painless and reduced visual acuity in both eyes who received tamoxifen therapy for 6 years. Tamoxifen-induced rentinopathy with CME showed significant development even though the patient has already discontinued tamoxifen treatment for 6 months. Anatomic improvements after intravitreal ranibizumab injection in both eyes were significant but were temporary. Surprisingly, CME in both eyes has been resolved spontaneously after 10 months in the penultimate visit without any therapy.
Intravitreal ranibizumab injection temporarily improved the anatomy of the eyes in a case with tamoxifen-induced CME, and only tamoxifen withdrawal can bring a sustained effect.
已有大量报道称他莫昔芬可引起眼部毒性,且主要表现为角膜病、白内障、视神经炎、黄斑裂孔、伴有或不伴有囊样黄斑水肿的晶体视网膜病变。停止使用他莫昔芬并获得肿瘤医生的认可,是治疗他莫昔芬诱导性视网膜病变的主要方法。
我们在此报告一例患者,该患者双眼无痛性视力下降 2 年,因乳腺癌接受他莫昔芬治疗 6 年。尽管患者已停止他莫昔芬治疗 6 个月,但仍出现伴 CME 的他莫昔芬诱导性视网膜病变且明显进展。尽管双眼玻璃体内注射雷珠单抗后解剖学改善显著,但却是暂时的。令人惊讶的是,在倒数第二次就诊时,双眼的 CME 在未经任何治疗的情况下 10 个月后自发消退。
在伴有 CME 的他莫昔芬诱导病例中,玻璃体内注射雷珠单抗可暂时改善眼部解剖结构,且只有停用他莫昔芬才能产生持续效果。